<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272647</url>
  </required_header>
  <id_info>
    <org_study_id>14-002829</org_study_id>
    <nct_id>NCT02272647</nct_id>
  </id_info>
  <brief_title>Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women</brief_title>
  <official_title>Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Progesterone amplifies estrogen-stimulated Growth Hormone (GH) secretion in postmenopausal
      women. Preliminary data are sought to estimate statistical power for more detailed studies of
      this hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The systemic availability and orderly secretion patterns of GH and sex steroids decline in
      healthy aging men and women. The combined changes have substantial clinical implications to
      aging-related physical frailty, diminished aerobic capacity, sarcopenia, osteopenia, visceral
      adiposity, glucose intolerance, and reduced psychosocial wellbeing. Whereas androgen is
      considered the main trophic (anabolic) sex steroid, recent data demonstrate that certain
      tissues respond principally to GH and testosterone-derived estradiol, Estrogen (E2) (e.g.
      bone, brain, liver and pituitary). In principle, frailty may thus be associated with dual GH
      and sex-steroid deficiencies. Additionally, young, but not older healthy women secrete
      significant amounts of progesterone for approximately 14 days during the luteal phase of
      every menstrual cycle. When GH levels rise nearly two fold, the investigators hypothesize
      that progesterone potentiates the GH response to E2. This hypothesis arises from scattered
      indirect studies often using synthetic progestins with partial androgen agonism, instead of
      progesterone per se.

      Because there is no basis for estimating statistical power for this novel paradigm, 40 women,
      10 each in 4 groups, will be studied. The pilot data will be used to calculate statistical
      power for a definitive R01-based investigation of gender-specific distinctions in
      estrogen-regulated pituitary-hormone secretion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Logarithm of the ratio of the normalized growth hormone secretion rate over the first 10 hr.</measure>
    <time_frame>The subject will be followed on average for a month. Growth hormone measurements will occur on Day 23 after initiation of study drug administration</time_frame>
    <description>Subjects will be given IM placebo/estradiol on Day 1. 10 days later they will receive IM placebo/estradiol again, then start progesterone/placebo capsules for 14 days. On Day 23, subjects will undergo a 12-h overnight (2200 - 1000h) fasting, 10-min blood sampling. The primary comparison parameter is the logarithm of the ratio of the normalized growth hormone secretion rate over the first 10 hr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth hormone secretion post ghrelin injection</measure>
    <time_frame>The subject will be followed on average for a month. Growth hormone measurements will occur on Day 23 after initiation of study drug administration</time_frame>
    <description>Subjects will be given IM placebo/estradiol on Day 1. 10 days later they will receive IM placebo/estradiol again, then start progesterone/placebo capsules for 14 days. On Day 23, subjects will undergo a 12-h overnight (2200 - 1000h) fasting, 10-min blood sampling. A secondary outcome is GH secretion over the 2 hr after bolus ghrelin injection, a potent growth hormone secretagogue</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Medroxyprogesterone (5 mg - for 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Saline Placebo (0.25 ml)</intervention_name>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Estradiol valerate (2.5 mg)</intervention_name>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Saline Placebo (0.5 ml)</intervention_name>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Estradiol valerate (5.0 mg)</intervention_name>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Micronized Progesterone</intervention_name>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ghrelin (0.3 ug/kg)</intervention_name>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone - Acetate</intervention_name>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>(in lieu of Medroxyprogesterone)</description>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women ages 50 to 80

          -  postmenopausal as defined by: any combination of the following

               -  Hormonally postmenopausal for 1 year

               -  Lh greater than 15 IU/L, FSH greater than 30 IU/L

               -  Total hysterectomy with oophorectomy greater than one year

               -  Hysterectomy with ovaries preserved with hormone levels: Lh &gt; 15 IU/L, FSH &gt; 30
                  IU/L

          -  Following laboratory results with normal range, unless PI approves out of range
             values.

          -  BMI 18 to 35

        Exclusion Criteria:

          -  structural hypothalamo-pituitary-gonadal disease

          -  endocrinopathy (diseases involving the following organs pituitary, thyroid, adrenals,
             ovaries, testes and pancreas), other than primary thyroid failure receiving
             replacement

          -  recent (within 2 weeks) estrogen, progestin, anabolic steroid or glucocorticoid use

          -  clinically significant ECG abnormality as determined by study team physicians

          -  obstructive uropathy

          -  history of a stroke

          -  history of MI or angina

          -  acute or chronic systemic disease

          -  recent transmeridian travel (traversing more than 3 time zones within 7 days of
             admission)

          -  current night shift work

          -  concurrent use of neuropsychiatric medications

          -  alcohol or drug abuse, current and within 2 years

          -  history of depression, psychosis, or mania

          -  weight gain or loss (2 kg or more in 3 weeks)

          -  BMI &gt; 35 kg/m2

          -  anemia, hemoglobin less than 12.5 g/dl

          -  abnormal hepatorenal function, creatinine outside normal range, ALT greater than two
             times normal range

          -  biochemical and chemistry lab results out of physician acceptable range

          -  history of deep-vein thrombophlebitis

          -  history of Congestive Heart Failure, cardiac arrhythmias, and medications used to
             treat cardiac arrhythmias

          -  known allergy to estradiol valerate, castor oil or sesame oil

          -  history of smoking within the last 2 years

          -  untreated gall bladder disease

          -  lack of voluntary, written informed consent

          -  history of carcinoma excluding localized basal cell or squamous cell, including women
             with known, suspected or history of breast cancer

          -  not clinically postmenopausal

          -  women with allergies to nuts will not be enrolled in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Johannes D. Veldhuis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Normal Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

